89Zr-DFO-zolbetuximab

89Zr-DFO-zolbetuximab is an investigational PET radiopharmaceutical designed for the non-invasive detection and molecular imaging of tumors expressing Claudin 18.2 (CLDN18.2). It consists of the monoclonal antibody zolbetuximab, which specifically binds to CLDN18.2, conjugated via the chelator deferoxamine (DFO) to the positron-emitting radioisotope zirconium-89 (89Zr). Developed by researchers at Massachusetts General Hospital, this agent serves as the diagnostic component of a theragnostic pair (alongside 177Lu-DOTA-zolbetuximab) to identify patients with high CLDN18.2 expression in gastric and pancreatic cancers. In preclinical studies, it has demonstrated high tumor uptake and the ability to guide targeted radiotherapy by identifying suitable candidates for treatment.

Other names

89Zr-zolbetuximabZirconium-89-DFO-zolbetuximabZirconium89-DFO-zolbetuximabZirconium 89-DFO-zolbetuximabclaudin 18.2-targeted PET radiopharmaceuticalclaudin18.2-targeted PET radiopharmaceuticalclaudin-18.2-targeted PET radiopharmaceutical